Moreover, of the 83 inhibitors, 20 are already in use for the treatment of LC in patients with ALK, BRAF, EGFR, ERBB2, MEK, MET, NTRK2 and RET alterations.11, 40. This evidence concerns the gene BRAF and laryngotracheoesophageal cleft.